Version history

{
  "session_id": "sess_SDA-2026-04-12-gap-debate-20260410-145418-c1527e7b_20260412-162950",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Mechanistic Hypotheses for AD Clinical Trial Failures\n\n---\n\n## Hypothesis 1: Proteostasis Network Collapse Precedes and Predominates Over Protein Aggregation\n\n**Title:** Early proteostasis failure in AD pathogenesis\n\n**Mechanism:** The integrated protein quality control system (UPS, autophagy-lysosome, heat-shock response) undergoes coordinated decline in AD brain, making Aβ/tau aggregation downstream epiphenomena of a more fundamental cellular homeostasis failure. Mutations in genes encoding proteostasis machinery (e.g., **HSP90**, **VCP**, **PSEN1/2** variants affecting ER-associated degradation) create a self-reinforcing collapse where protein aggregation overwhelms already-compromised clearance. Therapeutic targeting of downstream aggregation products (Aβ, tau) fails because the underlying clearance deficit remains unaddressed.\n\n**Key Evidence:**\n\n- Proteasome activity is significantly decreased in AD hippocampus (Keller et al., 2000, PMID: 10663926)\n- Autophagy-lysosomal dysfunction is a consistent early feature in AD brain, with autophagic vacuole accumulation in neurons (Nixon et al., 2005, PMID: 16186736)\n\n**Testable Prediction:** If proteostasis collapse is upstream, then neurons derived from AD-iPSCs engineered to overexpress master proteostasis regulators (e.g., **TFEB**, **HSF1**) should show reduced Aβ/tau aggregation without direct Aβ/tau targeting. Conversely, Aβ/tau-lowering strategies should fail to restore proteostasis markers in these same neurons.\n\n**Target Gene/Protein:** **TFEB** (Transcription Factor EB) — master regulator of lysosomal biogenesis and autophagy\n\n---\n\n## Hypothesis 2: Microglial State Transitions Are Directional and Irreversible in Established Disease\n\n**Title:** Microglial progression locks disease state\n\n**Mechanism:** Disease-associated microglia (DAM)/homeostatic activation state microglia (HAM) represent a unidirectional differentiation trajectory controlled by **TREM2**-**TYROBP** signaling and **APOE** isoform-dependent lipid sensing. In early disease, microglia may adopt a protective homeostatic state, but once transitioned to DAM/HAM (driven by **CX3CR1** downregulation, **APOE** e4-mediated lipid dysregulation), the state becomes self-reinforcing via epigenetic reprogramming. Amyloid-targeting trials fail because they cannot reverse this committed microglial state; by the time of clinical trial enrollment, the majority of patients have already passed the therapeutic window for microglial re-education.\n\n**Key Evidence:**\n\n- Single-cell RNA-seq reveals discrete microglial states in AD brain with TREM2-dependent DAM program (Keren-Shaul et al., 2017, PMID: 28602351)\n- TREM2 R47H variant increases AD risk and impairs microglial clustering around plaques (Griciuc et al., 2019, PMID: 31655654)\n\n**Testable Prediction:** If microglial state is locked, then single-cell ATAC-seq of microglia from early vs. late-stage AD patients should reveal distinct chromatin accessibility landscapes. Pharmacologic interventions (e.g., **TREM2 agonism**) should show efficacy only in early-stage but not late-stage patient-derived microglia in culture, predicting trial failure in symptomatic populations.\n\n**Target Gene/Protein:** **TREM2** (Triggering Receptor Expressed on Myeloid Cells 2)\n\n---\n\n## Hypothesis 3: Metabolic Zonation Creates Spatially-Distinct Therapeutic Windows\n\n**Title:** Metabolic vulnerability zones in AD cortex\n\n**Mechanism:** Brain energy metabolism exhibits microvascular zonation, with pericyte-covered capillaries creating metabolically distinct zones. **IDE** (insulin-degrading enzyme), **MECP2**, and mitochondrial complex I-IV subunits show decreased expression in these vulnerable zones. The \"type 3 diabetes\" hypothesis posits that brain insulin resistance (linked to **IRS1** hyperphosphorylation, **AKT** inhibition) specifically impairs glucose uptake in pericyte-enriched zones. Aβ may be a compensatory response to metabolic stress, explaining why Aβ-lowering",
  "tokens_used": "995"
}